[Seite 160↓]

Literatur

1. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319 (6050): 226-30.

2. Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982; 28 (4): 865-71.

3. Earp HS, Dawson TL, Li X, Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 1995; 35 (1): 115-32.

4. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230 (4730): 1132-9.

5. di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237 (4811): 178-82.

6. Segatto O, King CR, Pierce JH, di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988; 8 (12): 5570-4.

7. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-her2 receptor monoclonal antibody, inhibits basal and activated her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61 (12): 4744-9.

8. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999; 59 (6): 1196-201.

9. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991; 266 (3): 1716-20.

10. Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 1994; 5 (2-3): 313-29.

11. Bayer Corporation, Business Group Diagnostics. Bayer Immuno 1(TM) HER-2/neu Assay Clinical Report, 1999.

12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 (4785): 177-82.

13. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244 (4905): 707-12.

14. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 1995; 34 (4): 499-504.

15. Krainer M, Brodowicz T, Zeillinger R, Wiltschke C, Scholten C, Seifert M et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997; 54 (6): 475-81.


[Seite 161↓]

16. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999; 17 (7): 1974-82.

17. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19 (2): 354-63.

18. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999; 45 (8Pt1): 1148-56.

19. Revillion F, Hornez L, Peyrat JP. Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR. Clin Chem 1997; 43 (11): 2114-20.

20. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. First-line herceptin ((r)) monotherapy in metastatic breast cancer. Oncology 2001; 61 Suppl S2:37-42.

21. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19 (10): 2714-21.

22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783-92.

23. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16 (8): 2659-71.

24. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17 (9): 2639-48.

25. Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Luftner D et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 2001; 21 (2B): 1465-70.

26. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47 (1): 207-14.

27. Bayer Corporation, Business Group Diagnostics. Bayer Immuno 1 System Report, 1999.

28. Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001; 116 (4): 495-503.

29. Bauer KD, Torre-Bueno J, Diel IJ, Hawes D, Decker WJ, Priddy C et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000; 6 (9): 3552-9.

30. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat 1998; 52 (1-3): 305-19.


[Seite 162↓]

31. Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer 1999; 35 (1): 47-53.

32. Hayes DF. Tumor markers for breast cancer. Ann Oncol 1993; 4 (10): 807-19.

33. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988; 48 (14): 4107-12.

34. Basuyau JP, Blanc-Vincent MP, Bidart JM, Daver A, Deneux L, Eche N et al. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]. Bull Cancer 2000; 87 (10): 723-37.

35. Saghatchian M, Guepratte S, Floiras J, Paternostre B, and Pichon M. Correlation of serum ERBB-2 concentration with initial clinico-biological presentation and patients' outcome in primary breast cancer. Proc ASCO 2001; 20: 62b.

36. Brunner E. Nichtparametrische Analyse longitudinaler Daten. Oldenburg Verlag, München, Wien, Oldenburg, 1999.

37. Sachs L. Angewandte Statistik. Springer Verlag, Berlin, Heidelberg, New York, Ausgabe 9, 1999.

38. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997; 18 (3): 188-96.

39. Dia J. Clinical utility of an automated serum HER-2/neu assay in monitoring patients with metastatic breast cancer. Clin Chem 1998; 44 (6): A47.

40. Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY, Morris DL. Automated assay for HER-2/neu in serum. Clin Chem 2000; 46 (2): 175-82.

41. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13 (5): 1129-35.

42. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu nM et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998; 51 (2): 109-19.

43. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14 (3): 737-44.

44. Gion M, Mione R, Leon AE, Luftner D, Molina R, Possinger K et al. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001; 37 (3): 355-63.

45. Perissi V, Menini N, Cottone E, Capello D, Sacco M, Montaldo F et al. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 2000; 19 (2): 280-8.

46. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10 (12): 2435-46.


[Seite 163↓]

47. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM et al. HER-2 expression and response to tamoxifen in estrogen receptor- positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998; 4 (1): 7-12.

48. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BM et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991; 51 (12): 3296-303.

49. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992; 84 (16): 1279-82.

50. Kobayashi S, Iwase H, Itoh Y, Fukuoka H, Yamashita H, Kuzushima T et al. Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers. Jpn J Cancer Res 1992; 83 (8): 859-65.

51. Antoniotti S, Taverna D, Maggiora P, Sapei ML, Hynes NE, De Bortoli M. Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer 1994; 70 (6): 1095-101.

52. Bates NP, Hurst HC. An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 1997; 15 (4): 473-81.

53. Antoniotti S, Maggiora P, Dati C, De Bortoli M. Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 1992; 28 (2-3): 318-21.

54. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990; 5 (7): 1001-6.

55. Read LD, Keith D, Jr., Slamon DJ, Katzenellenbogen BS. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990; 50 (13): 3947-51.

56. Balsari A, Casalini P, Tagliabue E, Greco M, Pilotti S, Agresti R et al. Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. Am J Pathol 1999; 155 (5): 1543-7.

57. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18 (21): 3651-64.

58. Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, and Possinger K. Cyclophosphamide, methotrexate, and fluorouracil versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE Study (Takeda Adjuvant Breast Cancer Study with Leuprorelin acetate). Anticancer Res 2002; 22: 2325-32.

59. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19 (8): 2334-56.

60. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 1997; 11 (3Suppl2): 43-8.

61. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001; 19 (6): 1698-706.


[Seite 164↓]

62. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14 (10): 2702-8.

63. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19 (10): 2596-606.

64. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18 (7): 1399-411.

65. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19 (2): 343-53.

66. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18 (22): 3758-67.

67. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. Oncologist 2001; 6 (4): 376-85.

68. Thuerlimann B. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast Cancer 2001; 8 (4): 294-7.

69. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90 (18): 1346-60.

70. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330 (18): 1260-6.

71. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90 (18): 1361-70.

72. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10 (7): 1049-56.

73. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65 (1): 118-21.

74. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15 (7): 2518-25.

75. Bieche I, Onody P, Lerebours F, Tozlu S, Hacene K, Andrieu C et al. ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma. Cancer Lett 2001; 174 (2): 173-8.


[Seite 165↓]

76. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20 (14): 3095-105.

77. Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 1999; 17 (1): 434.

78. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 (7): 1800-8.

79. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20 (6): 1467-72.

80. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001; 7 (9): 2703-11.

81. Wong WL, Bajamonde A, Nelson B, Carney W, and Mass RD. Baseline serum HER2 (sHER2) levels in the pivotal Herceptin Breast Cancer Trials: A comparison of 2 ELISA methods. Proc ASCO 2000; 19: 77a.

82. Baron AT, Lafky JM, Connolly DC, Peoples J, O'Kane DJ, Suman VJ et al. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J Immunol Methods 1998; 219 (1-2): 23-43.

83. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC et al. Serum ErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1999; 8 (2): 129-37.

84. Lüftner D, Flath B, Henschke P, Geppert R, Wernecke KD, and Possinger K. Elevation of the serum HER2/neu and EGFR levels is associated with short progression-free survival in metastatic breast cancer. Breast Cancer Res Treat 2001; 69: 257.

85. Carney W, Burrell M, Morris L, and Hamer P. Normal levels of serum EGFr and decreases in several cancers. Proc AACR 2002; 43: 47.

86. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20 (4): 1000-7.

87. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93 (12): 913-20.

88. Marx III J, Leitzel K, Ali S, Carney W, Hamer P, Linnartz R, and Lipton A. Serum uPA in patients with pancreatic cancer. Proc AACR 2002; 43: 396.

89. Bon GG, van Kamp GJ, Verstraeten RA, Mensdorff-Pouilly S, Hilgers J, Kenemans P. Quantification of MUC1 in breast cancer patients. A method comparison study. Eur J Obstet Gynecol Reprod Biol 1999; 83 (1): 67-75.


[Seite 166↓]

90. Bon GG, Mensdorff-Pouilly S, Kenemans P, van Kamp GJ, Verstraeten RA, Hilgers J et al. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin Chem 1997; 43 (4): 585-93.

91. Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 2000; 15 (4): 343-56.

92. McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989; 4 (5): 543-8.

93. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6 (6): 2356-62.

94. Mehta RR, McDermott JH, Hieken TJ, Marler KC, Patel MK, Wild LD et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998; 16 (7): 2409-16.

95. Fehm T, Maimonis P, Katalinic A, Jager WH. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998; 55 (1): 33-8.

96. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997; 43 (1): 87-95.

97. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 2001; 12 Suppl 1:. S15-S19

98. Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 2001; 38 (2): 96-104.

99. Taverna D, Antoniotti S, Maggiora P, Dati C, De Bortoli M, Hynes NE. erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 1994; 56 (4): 522-8.

100. Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G et al. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 1995; 63 (4): 560-7.

101. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000; 19 (4): 490-7.

102. Bagli L, Dittadi R, Zancan M, Panzini I, Monti F, Ravaioli A. HER-2/neu serum levels and menopausal status. Int J Biol Markers 2001; 16 (1): 69-70.

103. Meden H, Mielke S, Marx D, Wuttke W, Kuhn W. Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 1997; 17 (4B): 3075-7.

104. Mielke S, Meden H, Raab T, Wuttke W, Kuhn W. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum. Anticancer Res 1997; 17 (4B): 3125-7.


[Seite 167↓]

105. Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thurlimann B, Rudenstam CM et al. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol 1997; 8 (8): 751-6.

106. Hagen AA, Hrushesky WJ. Menstrual timing of breast cancer surgery. Am J Surg 1998; 175 (3): 245-61.

107. Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C et al. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994; 343 (8912): 1545-7.

108. Oliver DJ, Ingram DM. Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors. Eur J Cancer 1995; 31A (3): 325-8.

109. Fentiman IS, Gregory WM, Richards MA. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994; 344 (8919): 402.

110. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993; 24 (2): 85-95.

111. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19 (18): 3808-16.

112. Pritchard KI. Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria? J Clin Oncol 2001; 19 (18): 3795-7.

113. Lipton A, Mouridsen H, Ali S, Leitzel K, Demers L, Harvey H, Chaudri-Ross HA, Brady C, Dugan M, and Carney W. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. Breast Cancer Res Treat 2002; 69: 210.

114. Stender MJ, Neuberg D, Wood W, Sledge G. Correlation of circulating c-erb B-2 extracellular domain (Her-2) with clinical outcome in patients with metastatic breast cancer(MBC). Proc ASCO 1997; 16: A541.

115. Gianni L, Capri G, Valagussa P, Bonadonna G. Putting taxanes to work in operable breast cancer: a search for selective indications from empirical studies. Recent Results Cancer Res 1998; 152: 314-22.

116. Volm M, Yee H, Symmans WF, Formenti S, Oratz R, Shapiro R et al. HER2 status predicts response to preoperative paclitaxel in patients with breast cancer. Proc ASCO 1999; 18:. A394

117. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15 (5): 537-47.

118. Konecny G, Thomssen C, Pegram M, Lück H, Untch M, Pauletti G et al. HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Proc ASCO 2001; 20: 23a.

119. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16 (10): 3353-61.

120. Perez EA, Irwin DH, Patel R, Vogel CL, Kirshner J. A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc ASCO 1999; 18:. 126a


[Seite 168↓]

121. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19 (10): 2587-95.

122. Sporn JR, Bilgrami SA. Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse after stem-cell transplant. Ann Oncol 1999; 10 (10): 1259-60.

123. Marx III J, Leitzel K, Ali S, Demers L, Almokadem S, Makhoul I, Carney W, Hamer P, Brady C, Dugan M, Wyld P, and Lipton A. Serum EGFR in metastatic breast cancer patients. Proc ASCO 2002; 21: 436a.

124. Baselga J. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. Ann Oncol 2002; 13 (1): 8-9.

125. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13 (1): 65-72.

126. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61 (24): 8887-95.

127. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61 (19): 7184-8.

128. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24 (3): 195-208.

129. Bast RC, Jr., Ravdin P, Hayes DF, Bates S, Fritsche H, Jr., Jessup JM et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19 (6): 1865-78.

130. Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers 2000; 15 (4): 330-3.

131. Ebeling FC, Schmitt UM, Untch M, Nagel D, Fateh-Moghadam A, Stieber P et al. Tumour markers CEA and CA 15-3 as prognostic factors in breast cancer--univariate and multivariate analysis. Anticancer Res 1999; 19 (4A): 2545-50.

132. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002; 48 (8): 1314-20.

133. Kostler W, Schwab B, Singer C, Neumann R, Marton E, Brodowicz T, Tomek S, Steger G, Wiltschke C, Krainer M, and Zielinski C. Serial monitoring of serum HER-2/neu extracellular domain (ECD) can predict response to trastuzumab-based therapy in patients with breast cancer. Proc ASCO 2002; 21: 17a.

134. Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 1997; 73 (6): 875-9.

135. Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001; 19 (3): 645-56.


[Seite 169↓]

136. Gandour-Edwards R, Liu HL, Lara PN, de Vere-White R, and LaSalle JM. Detection of low level HER-2/neu gene amplification in prostate cancer (CAP) by fluorescent in situ hybridisation (FISH). Proc ASCO 2001; 20: 733.

137. Simojoki M, Santala M, Risteli J, Kauppila A. Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer. Gynecol Oncol 2001; 82 (1): 110-5.

138. Santala M, Risteli J, Risteli L, Puistola U, Kacinski BM, Stanley ER et al. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer. Br J Cancer 1998; 77 (11): 1825-31.

139. Santala M, Simojoki M, Risteli J, Risteli L, Kauppila A. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999; 5 (12): 4091-6.

140. Harris L, Luftner D, Jager W, Robertson JF. c-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 1999; 14 (1): 8-15.

141. Raemaekers JM, Beex LV, Koenders AJ, Pieters GF, Smals AG, Benraad TJ et al. Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol 1984; 20 (8): 1011-8.

142. Hull DF, III, Clark GM, Osborne CK, Chamness GC, Knight WA, III, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43 (1): 413-6.

143. Li BD, Byskosh A, Molteni A, Duda RB. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994; 57 (2): 71-7.

144. Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001; 12 (5): 615-20.

145. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000; 18 (1): 87-93.

146. Edgerton SM, Merkel DE, Moore DH, Thor AD. HER-2/neu/ErbB-2 status by immunohistochemistry and FISH: Clonality and progression with recurrence and metastases. Breast Cancer Res Treat 2000; 64 (1): 55.

147. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93 (15): 1141-6.

148. Chariyalertsak S, Sugano K, Ohkura H, Mori Y. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol 1994; 15 (5): 294-303.

149. Jimenez RE, Grignon DJ, Vaishampayan U, Hussain M. Analysis of HER-2/neu overexpression in primary and metastatic transitional cell carcinoma of the bladder. Proc ASCO 2000; 19:. 329a

150. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5 (3): 280-5.

151. Roetger A, Merschjann A, Dittmar T, Jackisch C, Barnekow A, Brandt B. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol 1998; 153 (6): 1797-806.


[Seite 170↓]

152. Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G et al. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein- positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer 1998; 76 (6): 824-8.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
06.02.2004